Benzinga | Nov 2, 2021 10:52AM EDT

Pieris Pharmaceuticals Q3 EPS $(0.24), Inline, Sales $4.06M Miss $5.32M Estimate

Pieris Pharmaceuticals (NASDAQ:PIRS) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate. This is a 7.69 percent increase over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $4.06 million which missed the analyst consensus estimate of $5.32 million by 23.74 percent. This is a 38.04 percent increase over sales of $2.94 million the same period last year.